Lymphoma, Hodgkin
16
4
6
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
2 terminated out of 16 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
STAY-STRONG Study of Exercise Training During Chemotherapy
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
Precision Exercise in Children With Malignant Hemopathies
Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of Lymphoma
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
MELT - MRI Evaluation of Lymphoma Treatment